Pomanda estimates the enterprise value of ADVANZ PHARMA GENERICS (UK) LIMITED at £56.5k based on a Turnover of £46.6k and 1.21x industry multiple (adjusted for size and gross margin).
Pomanda estimates the enterprise value of ADVANZ PHARMA GENERICS (UK) LIMITED at £10.5k based on an EBITDA of £2k and a 5.25x industry multiple (adjusted for size and gross margin).
Pomanda estimates the enterprise value of ADVANZ PHARMA GENERICS (UK) LIMITED at £20.3k based on Net Assets of £10.4k and 1.95x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Advanz Pharma Generics (uk) LimitedOverview
Advanz Pharma Generics (uk) Limited is a live company located in london, EC2M 1QS with a Companies House number of 02760679. It operates in the manufacture of pharmaceutical preparations sector, SIC Code 21200. Founded in October 1992, it's largest shareholder is
mercury pharma group limited
with a 100% stake. Advanz Pharma Generics (uk) Limited is a mature,
micro sized company, Pomanda has estimated its turnover at
£46.6k with
declining
growth in recent years.
Pomanda's financial health check has awarded Advanz Pharma Generics (Uk) Limited a 1.5 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 8 areas for improvement. Company Health Check FAQs
Health Rating1.5out of 5
1 Strong
1 Regular
8 Weak
Size
annual sales of £46.6k, make it smaller than the average company (£35m)
£46.6k - Advanz Pharma Generics (uk) Limited
£35m - Industry AVG
Growth
3 year (CAGR) sales growth of -90%, show it is growing at a slower rate (4.5%)
-90% - Advanz Pharma Generics (uk) Limited
4.5% - Industry AVG
Production
with a gross margin of 30.9%, this company has a comparable cost of product (32.9%)
30.9% - Advanz Pharma Generics (uk) Limited
32.9% - Industry AVG
Profitability
an operating margin of 4.3% make it less profitable than the average company (8.9%)
4.3% - Advanz Pharma Generics (uk) Limited
8.9% - Industry AVG
Employees
with 1 employees, this is below the industry average (102)
1 - Advanz Pharma Generics (uk) Limited
102 - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- - Advanz Pharma Generics (uk) Limited
- - Industry AVG
Efficiency
resulting in sales per employee of £46.6k, this is less efficient (£382.3k)
£46.6k - Advanz Pharma Generics (uk) Limited
£382.3k - Industry AVG
Debtor Days
it gets paid by customers after 91 days, this is later than average (53 days)
91 days - Advanz Pharma Generics (uk) Limited
53 days - Industry AVG
Creditor Days
its suppliers are paid after 2 days, this is quicker than average (34 days)
2 days - Advanz Pharma Generics (uk) Limited
34 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Advanz Pharma Generics (uk) Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 13 weeks, this is more cash available to meet short term requirements (10 weeks)
13 weeks - Advanz Pharma Generics (uk) Limited
10 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 58.7%, this is a higher level of debt than the average (44.4%)
58.7% - Advanz Pharma Generics (uk) Limited
44.4% - Industry AVG
ADVANZ PHARMA GENERICS (UK) LIMITED financials
EXPORT
Advanz Pharma Generics (Uk) Limited's latest turnover from December 2023 is £46.6 thousand and the company has net assets of £10.4 thousand. According to their latest financial statements, we estimate that Advanz Pharma Generics (Uk) Limited has 1 employee and maintains cash reserves of £3.7 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Mar 2012
Mar 2011
Mar 2010
Turnover
46,596
42,003
41,021
40,596,647
47,517,519
38,657,701
46,653,383
74,734,603
52,491,384
29,283,345
27,465,480
20,004,238
13,160,822
13,076,481
11,414,519
Other Income Or Grants
Cost Of Sales
32,186
29,477
28,467
27,781,234
32,580,618
25,394,962
30,554,928
44,675,350
35,276,439
20,243,634
5,926,112
4,659,960
3,987,681
3,922,599
4,107,259
Gross Profit
14,410
12,526
12,554
12,815,413
14,936,901
13,262,739
16,098,455
30,059,253
17,214,945
9,039,711
21,539,368
15,344,278
9,173,141
9,153,882
7,307,260
Admin Expenses
12,410
10,721
10,790
11,069,758
12,893,649
11,600,457
14,092,361
19,912,428
9,406,358
6,418,968
3,808,584
9,185,137
2,651,023
3,557,305
2,764,076
Operating Profit
2,000
1,805
1,764
1,745,655
2,043,252
1,662,282
2,006,094
10,146,825
7,808,587
2,620,743
17,730,784
6,159,141
6,522,118
5,596,577
4,543,184
Interest Payable
Interest Receivable
72
6
9,017
37,970
28,218
1,426
68,870
541
26
13
114
Pre-Tax Profit
2,072
1,811
1,764
1,754,672
2,081,222
1,690,500
2,007,520
10,215,695
7,808,587
2,620,743
17,730,784
6,159,682
6,522,144
5,596,590
4,543,298
Tax
-321,195
-386,448
-2,043,139
-1,581,927
-560,310
-2,961,319
-2,053,030
-1,313,655
-1,581,429
-1,313,873
Profit After Tax
2,072
1,811
1,764
1,754,672
2,081,222
1,369,305
1,621,072
8,172,556
6,226,660
2,060,433
14,769,465
4,106,652
5,208,489
4,015,161
3,229,425
Dividends Paid
2,000,000
6,000,000
6,000,000
Retained Profit
2,072
1,811
1,764
1,754,672
2,081,222
-630,695
1,621,072
8,172,556
6,226,660
2,060,433
14,769,465
4,106,652
-791,511
4,015,161
-2,770,575
Employee Costs
7,687,457
4,989,339
4,804,438
3,166,721
185,716
248,565
126,599
Number Of Employees
1
1
1
118
134
108
139
293
207
109
110
76
49
52
49
EBITDA*
2,000
1,805
1,764
1,745,655
2,043,252
1,662,282
2,006,094
10,146,825
7,808,587
2,620,743
17,730,784
6,159,141
6,522,118
5,596,577
4,543,184
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Mar 2012
Mar 2011
Mar 2010
Tangible Assets
Intangible Assets
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
Stock & work in progress
Trade Debtors
11,722
13,286
9,289
9,582,890
10,439,230
9,013,254
9,565,330
12,803,429
11,786,522
5,208,725
5,694,483
5,944,683
3,871,833
2,265,977
1,815,345
Group Debtors
9,689
10,423
549
6,168
392,569
897,007
2,894,984
24,630,924
26,100,182
25,156,800
17,023,926
8,010,473
6,182,960
3,824,001
Misc Debtors
20
39
19
18,025
18,025
15,081
15,581
12,036
17,207
7,500
500
1,049
8,485
11,493
Cash
3,711
1,877
6,566
7,991,801
7,881,900
14,031,662
7,273,446
2,021,852
10,841,979
2,184,168
1,380,722
299,612
625,258
4,871,718
1,024,603
misc current assets
total current assets
25,142
25,625
16,423
17,598,884
18,731,724
23,957,004
16,854,357
17,732,301
47,276,632
33,500,575
32,232,505
23,269,270
12,516,049
13,332,148
6,663,949
total assets
25,142
25,625
16,423
17,598,884
18,731,724
23,957,004
16,854,357
17,732,301
47,276,632
33,500,575
32,232,505
23,269,270
12,516,049
13,332,148
6,663,949
Bank overdraft
Bank loan
Trade Creditors
239
228
98
21,616
258,328
363
285
31,752
146,762
169,280
176,399
35,237
73,254
Group/Directors Accounts
12,484
14,190
7,374
10,222,063
12,324,177
21,555,019
13,150,723
11,696,056
9,432,300
3,675,055
346,750
5,961,141
2,020,447
2,363,245
204,060
other short term finances
hp & lease commitments
other current liabilities
2,042
2,902
2,457
2,625,451
3,174,137
1,507,762
2,178,794
6,132,762
3,113,405
1,289,501
5,295,159
5,464,480
2,751,486
2,574,438
2,042,568
total current liabilities
14,765
17,320
9,929
12,869,130
15,756,642
23,063,144
15,329,802
17,828,818
12,545,705
4,996,308
5,788,671
11,594,901
4,948,332
4,972,920
2,319,882
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
total liabilities
14,765
17,320
9,929
12,869,130
15,756,642
23,063,144
15,329,802
17,828,818
12,545,705
4,996,308
5,788,671
11,594,901
4,948,332
4,972,920
2,319,882
net assets
10,377
8,305
6,494
4,729,754
2,975,082
893,860
1,524,555
-96,517
34,730,927
28,504,267
26,443,834
11,674,369
7,567,717
8,359,228
4,344,067
total shareholders funds
10,377
8,305
6,494
4,729,754
2,975,082
893,860
1,524,555
-96,517
34,730,927
28,504,267
26,443,834
11,674,369
7,567,717
8,359,228
4,344,067
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Mar 2012
Mar 2011
Mar 2010
Operating Activities
Operating Profit
2,000
1,805
1,764
1,745,655
2,043,252
1,662,282
2,006,094
10,146,825
7,808,587
2,620,743
17,730,784
6,159,141
6,522,118
5,596,577
4,543,184
Depreciation
Amortisation
Tax
-321,195
-386,448
-2,043,139
-1,581,927
-560,310
-2,961,319
-2,053,030
-1,313,655
-1,581,429
-1,313,873
Stock
Debtors
-2,317
13,891
-9,597,226
-1,242,741
924,482
344,431
-6,129,538
-20,724,204
5,118,246
464,624
7,882,125
14,509,228
3,430,361
2,821,084
5,639,346
Creditors
11
130
-21,518
-236,712
257,965
78
285
-31,752
-115,010
-22,518
134,043
141,162
-38,017
73,254
Accruals and Deferred Income
-860
445
-2,622,994
-548,686
1,666,375
-671,032
-3,953,968
3,019,357
1,823,904
-4,005,658
-169,321
2,890,042
177,048
531,870
2,042,568
Deferred Taxes & Provisions
Cash flow from operations
3,468
-11,511
6,954,478
2,202,998
3,043,110
325,702
3,795,501
31,847,247
2,900,566
-2,524,859
6,695,501
-7,379,032
2,096,312
1,687,917
-294,213
Investing Activities
capital expenditure
Change in Investments
cash flow from investments
Financing Activities
Bank loans
Group/Directors Accounts
-1,706
6,816
-10,214,689
-2,102,114
-9,230,842
8,404,296
1,454,667
2,263,756
5,757,245
3,328,305
-5,614,391
3,597,896
-342,798
2,159,185
204,060
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
-4,725,024
-43,000,000
-791,511
7,114,642
interest
72
6
9,017
37,970
28,218
1,426
68,870
541
26
13
114
cash flow from financing
-1,634
6,822
-14,939,713
-2,093,097
-9,192,872
8,432,514
1,456,093
-40,667,374
5,757,245
3,328,305
-5,614,391
2,806,926
-342,772
2,159,198
7,318,816
cash and cash equivalents
cash
1,834
-4,689
-7,985,235
109,901
-6,149,762
6,758,216
5,251,594
-8,820,127
8,657,811
803,446
1,081,110
-4,572,106
-4,246,460
3,847,115
1,024,603
overdraft
change in cash
1,834
-4,689
-7,985,235
109,901
-6,149,762
6,758,216
5,251,594
-8,820,127
8,657,811
803,446
1,081,110
-4,572,106
-4,246,460
3,847,115
1,024,603
advanz pharma generics (uk) limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for advanz pharma generics (uk) limited. Get real-time insights into advanz pharma generics (uk) limited's credit score, group structure and payment trends.
Perform a competitor analysis for advanz pharma generics (uk) limited by selecting its closest rivals, whether from the MANUFACTURING sector, other micro companies, companies in EC2M area or any other competitors across 12 key performance metrics.
advanz pharma generics (uk) limited Ownership
ADVANZ PHARMA GENERICS (UK) LIMITED group structure
Advanz Pharma Generics (Uk) Limited has no subsidiary companies.
The sole shareholder of Advanz Pharma Generics (Uk) Limited is Mercury Pharma Group Limited.
mercury pharma group limited
100%
advanz pharma generics (uk) limited directors
Advanz Pharma Generics (Uk) Limited currently has 2 directors.
The longest serving directors include
Mr Andreas Stickler (Jan 2022) and
Mr Melvin Ferry (Feb 2025).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 11 charges/mortgages relating to advanz pharma generics (uk) limited. Currently there are 1 open charges and 10 have been satisfied in the past.
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ADVANZ PHARMA GENERICS (UK) LIMITED. This can take several minutes, an email will notify you when this has completed.
advanz pharma generics (uk) limitedCompanies House Filings - See Documents
